Cannabigeroquinone compounds, compositions including such compounds, and uses of such compounds and compositions

A method of treating, ameliorating, or preventing the recurrence of an inflammatory condition selected from the group consisting of acute inflammation, chronic inflammation, developmental inflammation, meta-inflammation and inflammaging in a subject having an inflammatory condition, comprising:

• administering an effective dose of a composition comprising (i) at least one of a pharmaceutically effective carrier, a pharmaceutically effective diluent, and a pharmaceutically effective excipient, and (ii) a compound of formula (I) or formula (Ia):
• wherein RA and RB are each selected from the group consisting of:
• —H, —F, —Cl, —Br, —I, —CH3, —CH2CH3, —CF3, —OH, —OCH3, —OCH2CH3, —OCONH2, —O(CO)CH3, —O(CO)CH2CH3, —CN, —NH2, —NHCH2CH2CH3, —NHCH2CH3, —N(CH3)2 and —NHCH(CH3)2;
• wherein each of X and Y are independently selected from the group consisting of:
• —OH, ═O, —OCH3, —OCOCH3 and —OCOCH2CH3;
• wherein R is a moiety of formula (II):
• wherein each dashed line is independently selected from representing a carbon-carbon single bond and representing a carbon-carbon double bond;
• wherein R2 is either a moiety of the formula (III-A), —(CH2)nCH3, wherein n in an integer greater than one and less than seven, or a moiety of the formula (III-B), —(CH2)m(CH═CH)(CH2)pCH3, wherein m is an integer greater than zero and less than four, and wherein p is an integer greater than or equal to zero and less than four, and wherein the sum of m and p is not greater than four;
• and
• with the caveat that the compound is not any of the following compounds:

A method of treating, ameliorating, reducing, or preventing the recurrence of a one or more symptom of a disease or disorder in a subject in need thereof, the method comprising:

• administering a compound of formula (I) or formula (Ia):
• wherein each of RA and RB is independently selected from the group consisting of:
• —H, —F, —Cl, —Br, —I, —CH3, —CH2CH3, —CF3, —OH, —OCH3, —OCH2CH3, —O(CO)NH2, —O(CO)CH3, —O(CO)CH2CH3, —CN, —NH2, —NHCH2CH2CH3, —NHCH2CH3, —N(CH3)2 and —NHCH(CH3)2;
• wherein each of X and Y is independently selected from the group consisting of:
• —OH, ═O, —OCH3, —O(CO)CH3 and —O(CO)CH2CH3;
• wherein R is a moiety of formula (II):
• wherein each dashed bond is individually selected from representing a carbon-carbon single bond and representing a carbon-carbon double bond;
• wherein R2 is a moiety of formula (III):
• wherein the dashed bond is selected from representing a carbon-carbon single bond and representing a carbon-carbon double bond;
• and
• wherein the disease or disorder is associated with the activity of or the expression of one or more of TNF, IL-6, IL-1β, IL10, IFNg, Lox5, CB2, and/or Lox15.